JP6530742B2 - 腸内病原体の免疫応答を強化する組成物及び方法 - Google Patents
腸内病原体の免疫応答を強化する組成物及び方法 Download PDFInfo
- Publication number
- JP6530742B2 JP6530742B2 JP2016502428A JP2016502428A JP6530742B2 JP 6530742 B2 JP6530742 B2 JP 6530742B2 JP 2016502428 A JP2016502428 A JP 2016502428A JP 2016502428 A JP2016502428 A JP 2016502428A JP 6530742 B2 JP6530742 B2 JP 6530742B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- vaccine vector
- amino acid
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000028993 immune response Effects 0.000 title claims description 75
- 238000000034 method Methods 0.000 title claims description 56
- 230000002708 enhancing effect Effects 0.000 title claims description 11
- 239000000203 mixture Substances 0.000 title description 22
- 244000000021 enteric pathogen Species 0.000 title description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 237
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 231
- 229920001184 polypeptide Polymers 0.000 claims description 228
- 239000013598 vector Substances 0.000 claims description 206
- 229960005486 vaccine Drugs 0.000 claims description 189
- 108091033319 polynucleotide Proteins 0.000 claims description 102
- 102000040430 polynucleotide Human genes 0.000 claims description 102
- 239000002157 polynucleotide Substances 0.000 claims description 102
- 230000000890 antigenic effect Effects 0.000 claims description 74
- 150000001413 amino acids Chemical class 0.000 claims description 60
- 102100037907 High mobility group protein B1 Human genes 0.000 claims description 51
- 241000894007 species Species 0.000 claims description 50
- 241000894006 Bacteria Species 0.000 claims description 44
- 230000003308 immunostimulating effect Effects 0.000 claims description 43
- 241000607142 Salmonella Species 0.000 claims description 40
- 241000287828 Gallus gallus Species 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 24
- 230000002163 immunogen Effects 0.000 claims description 23
- 241000282414 Homo sapiens Species 0.000 claims description 21
- 101150013553 CD40 gene Proteins 0.000 claims description 19
- 241000607598 Vibrio Species 0.000 claims description 19
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 10
- 241000588698 Erwinia Species 0.000 claims description 8
- 241000588748 Klebsiella Species 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 108700010013 HMGB1 Proteins 0.000 claims description 7
- 241000607768 Shigella Species 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 244000144977 poultry Species 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 241000588923 Citrobacter Species 0.000 claims description 6
- 241000588722 Escherichia Species 0.000 claims description 6
- 125000006850 spacer group Chemical group 0.000 claims description 6
- 241000588768 Providencia Species 0.000 claims description 5
- 230000005875 antibody response Effects 0.000 claims description 5
- 229940126580 vector vaccine Drugs 0.000 claims description 5
- 230000005867 T cell response Effects 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 101150021904 HMGB1 gene Proteins 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 230000003362 replicative effect Effects 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 241000607149 Salmonella sp. Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims 2
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 claims 1
- 241000488157 Escherichia sp. Species 0.000 claims 1
- 241000186610 Lactobacillus sp. Species 0.000 claims 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims 1
- 102100033288 Leucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containing protein 1 Human genes 0.000 description 55
- 235000001014 amino acid Nutrition 0.000 description 51
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 50
- 239000000427 antigen Substances 0.000 description 35
- 102000036639 antigens Human genes 0.000 description 35
- 108091007433 antigens Proteins 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 28
- 244000052769 pathogen Species 0.000 description 25
- 235000013330 chicken meat Nutrition 0.000 description 19
- 241000193830 Bacillus <bacterium> Species 0.000 description 15
- 230000001580 bacterial effect Effects 0.000 description 15
- 108091005703 transmembrane proteins Proteins 0.000 description 15
- 102000035160 transmembrane proteins Human genes 0.000 description 15
- 235000014469 Bacillus subtilis Nutrition 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 101150077062 pal gene Proteins 0.000 description 14
- 101150012565 LRIT1 gene Proteins 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 9
- 206010022000 influenza Diseases 0.000 description 9
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 8
- 210000002421 cell wall Anatomy 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 238000003305 oral gavage Methods 0.000 description 8
- 238000000540 analysis of variance Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000607726 Salmonella enterica subsp. enterica serovar Heidelberg Species 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 210000004534 cecum Anatomy 0.000 description 6
- 230000012447 hatching Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 101150012518 lamB gene Proteins 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 241000589876 Campylobacter Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102000055207 HMGB1 Human genes 0.000 description 4
- 241000520272 Pantoea Species 0.000 description 4
- 241000588769 Proteus <enterobacteria> Species 0.000 description 4
- 241000607720 Serratia Species 0.000 description 4
- 241001660101 Sodalis Species 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 231100000221 frame shift mutation induction Toxicity 0.000 description 4
- 230000037433 frameshift Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 210000000680 phagosome Anatomy 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000252983 Caecum Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241001187099 Dickeya Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 241000531155 Pectobacterium Species 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 108010008038 Synthetic Vaccines Proteins 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 229940124551 recombinant vaccine Drugs 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000034573 Channels Human genes 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 101100082138 Citrus limon PAL6 gene Proteins 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101150072055 PAL1 gene Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 101100192827 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PXA1 gene Proteins 0.000 description 2
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 2
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 101100398653 Yersinia pestis lamB1 gene Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 101150101706 cotB gene Proteins 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 102000036072 fibronectin binding proteins Human genes 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 102000053637 human HMGB1 Human genes 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100024113 40S ribosomal protein S15a Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000224482 Apicomplexa Species 0.000 description 1
- 101100178203 Arabidopsis thaliana HMGB3 gene Proteins 0.000 description 1
- 101100478373 Bacillus subtilis (strain 168) srtD gene Proteins 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101001022455 Dichelobacter nodosus Probable minor fimbrial protein Proteins 0.000 description 1
- 101001063133 Dichelobacter nodosus Type IV major fimbrial protein FimA Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588699 Erwinia sp. Species 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 101100339421 Gallus gallus HMGB1 gene Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101150091750 HMG1 gene Proteins 0.000 description 1
- 101001118566 Homo sapiens 40S ribosomal protein S15a Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 101900330356 Influenza A virus Matrix protein 2 Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 241000588754 Klebsiella sp. Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000588774 Providencia sp. Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000607758 Shigella sp. Species 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000607284 Vibrio sp. Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607757 Xenorhabdus Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 101150087718 srtA gene Proteins 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- HPQYKCJIWQFJMS-UHFFFAOYSA-L tetrathionate(2-) Chemical compound [O-]S(=O)(=O)SSS([O-])(=O)=O HPQYKCJIWQFJMS-UHFFFAOYSA-L 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/107—Vibrio
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790301P | 2013-03-15 | 2013-03-15 | |
| US61/790,301 | 2013-03-15 | ||
| PCT/US2014/027416 WO2014152508A1 (en) | 2013-03-15 | 2014-03-14 | Compositions and methods of enhancing immune responses to enteric pathogens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515133A JP2016515133A (ja) | 2016-05-26 |
| JP2016515133A5 JP2016515133A5 (OSRAM) | 2017-04-13 |
| JP6530742B2 true JP6530742B2 (ja) | 2019-06-12 |
Family
ID=51581229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502428A Active JP6530742B2 (ja) | 2013-03-15 | 2014-03-14 | 腸内病原体の免疫応答を強化する組成物及び方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10376571B2 (OSRAM) |
| EP (2) | EP2968423A4 (OSRAM) |
| JP (1) | JP6530742B2 (OSRAM) |
| KR (1) | KR102239207B1 (OSRAM) |
| CN (1) | CN105142653B (OSRAM) |
| AR (1) | AR095313A1 (OSRAM) |
| AU (1) | AU2014239557B2 (OSRAM) |
| BR (1) | BR112015023024B1 (OSRAM) |
| CA (1) | CA2906079C (OSRAM) |
| CL (2) | CL2015002741A1 (OSRAM) |
| EA (1) | EA033538B1 (OSRAM) |
| HK (1) | HK1219045A1 (OSRAM) |
| MX (1) | MX376350B (OSRAM) |
| MY (1) | MY173901A (OSRAM) |
| PH (1) | PH12015502135A1 (OSRAM) |
| SG (1) | SG11201507421XA (OSRAM) |
| WO (1) | WO2014152508A1 (OSRAM) |
| ZA (1) | ZA201506466B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| HUE047164T2 (hu) * | 2007-11-01 | 2020-04-28 | Univ Arkansas | Kompozíciók és eljárások eimeria elleni immunválasz fokozására |
| EP2956165B1 (en) | 2013-02-14 | 2019-09-11 | The Board of Trustees of the University of Arkansas | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
| AR095313A1 (es) * | 2013-03-15 | 2015-10-07 | Univ Arkansas | Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| SG11201809686SA (en) * | 2016-05-03 | 2018-11-29 | Univ Arkansas | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same |
| CN106124772B (zh) * | 2016-06-15 | 2018-05-04 | 金华职业技术学院 | 一种基于omp18检测空肠弯曲菌的elisa检测试剂盒及其应用 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| PE20251181A1 (es) * | 2017-06-07 | 2025-04-23 | Spark Therapeutics Inc | Agentes potenciadores para la transfeccion celular mejorada y/o la produccion del vector raav |
| US20210369836A1 (en) * | 2020-05-26 | 2021-12-02 | Synlogic Operating Company, Inc. | Surface display of proteins on recombinant bacteria and uses thereof |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69229221T2 (de) | 1991-03-05 | 1999-09-23 | The Wellcome Foundation Ltd., Greenford | Expression rekombinanter proteine in attenuierten bakterien |
| US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
| US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
| JP3308534B2 (ja) | 1991-10-25 | 2002-07-29 | イミュネックス・コーポレーション | 新規なサイトカイン |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
| EP0659086B1 (en) | 1992-09-04 | 1998-11-11 | The University of Saskatchewan | Novel bacterial vaccines using vaccine strains of pathogenic bacteria |
| AU1059095A (en) | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
| GB9420146D0 (en) * | 1994-10-06 | 1994-11-23 | Cancer Res Campaign Tech | Papillomavirus vaccine |
| CA2213798C (en) | 1995-03-01 | 2001-02-06 | Immunex Corporation | Method for stimulating an immune response |
| KR100453314B1 (ko) | 1995-06-07 | 2004-12-17 | 임뮤넥스 코포레이션 | Cd40l 돌연변이 단백질 |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6306387B1 (en) | 1997-05-29 | 2001-10-23 | The Research Foundation Of State University Of New York | Antigen delivery system |
| US20030045492A1 (en) | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| CA2223225A1 (en) | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
| CA2313805A1 (en) | 1997-12-19 | 1999-07-01 | Immunex Corporation | Method for reducing susceptibility to hiv infection |
| GB9806449D0 (en) | 1998-03-25 | 1998-05-27 | Peptide Therapeutics Ltd | Attenuated bacteria useful in vaccines |
| US6190669B1 (en) | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
| IT1299583B1 (it) | 1998-05-19 | 2000-03-16 | Vander Way Limited | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
| DE69939264D1 (de) | 1998-09-04 | 2008-09-18 | Emergent Product Dev Uk Ltd | Attenuierte salmonella spi2 mutante als antigen-träger |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| EP1067194A1 (en) | 1999-04-16 | 2001-01-10 | F. Hoffmann-La Roche Ag | Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
| IL144952A0 (en) | 1999-04-16 | 2002-06-30 | Hoffmann La Roche | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| CA2382221A1 (en) * | 1999-08-20 | 2001-03-01 | H. Shaw Warren | Outer membrane protein a, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis |
| WO2001026608A2 (en) | 1999-10-14 | 2001-04-19 | Ledbetter Jeffrey A | Dna vaccines encoding antigen linked to a domain that binds cd40 |
| DE60011560T2 (de) | 1999-12-28 | 2005-08-18 | Akzo Nobel N.V. | Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert |
| CA2393616A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US7371392B2 (en) | 2000-02-02 | 2008-05-13 | The United States Of America As Represented By The Department Of Health And Human Services | Cd40 ligand adjuvant for respiratory syncytial virus |
| AU2001256957B2 (en) | 2000-03-17 | 2005-08-25 | Pharmacia & Upjohn Company Llc | Salmonella vaccine materials and methods |
| GB0015426D0 (en) | 2000-06-24 | 2000-08-16 | Univ Southampton | Method for generating soluble highly multimeric proteins |
| US20030165538A1 (en) | 2000-06-26 | 2003-09-04 | Maxygen Incorporated | Methods and compositions for developing spore display systems for medicinal and industrial applications |
| WO2002036769A2 (en) | 2000-10-31 | 2002-05-10 | F. Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| PT1407004E (pt) | 2001-05-15 | 2009-08-31 | Ortho Mcneil Janssen Pharm | Iniciação ex-vivo para produção de linfócitos t citotóxicos específicos de ligando-cd40 para tratar doenças autoimunes e alérgicas |
| CN100447154C (zh) | 2001-05-15 | 2008-12-31 | 费因斯坦医学研究学院 | 利用hmg片段作为抗炎症试剂 |
| ITMI20011986A1 (it) | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
| AU2002358771B2 (en) | 2001-12-19 | 2009-04-23 | Alcedo Biotech Gmbh | Use of HMGB proteins and nucleic acids that code therefor |
| ATE399180T1 (de) | 2001-12-21 | 2008-07-15 | Immunex Corp | Rekombinante polypeptide |
| EP1487273B1 (en) | 2002-02-13 | 2009-01-21 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
| US6923958B2 (en) | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
| EP1499191B1 (en) | 2002-04-15 | 2012-05-09 | Washington University in St. Louis | Regulated attenuation of live vaccines to enhance cross protective immunogenicity |
| US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| US20040156851A1 (en) | 2002-11-20 | 2004-08-12 | Critical Therapeutics, Inc. | HMGB1 combination therapies |
| US20060121047A1 (en) | 2002-11-20 | 2006-06-08 | Tracey Kevin J | Use of hmgb polypetides for increasing immune responses |
| WO2004046345A2 (en) | 2002-11-20 | 2004-06-03 | Critical Therapeutics, Inc. | Use of hmgb fragments as anti-inflammatory agents |
| US20040141948A1 (en) | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
| US20050181994A1 (en) | 2003-01-06 | 2005-08-18 | Xencor, Inc. | Novel variants of CD40L protein |
| US20060014248A1 (en) | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| WO2005025604A2 (en) | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
| WO2005035570A2 (en) | 2003-10-10 | 2005-04-21 | Xencor, Inc. | Variants of cd40l protein |
| US20070178110A1 (en) | 2003-11-21 | 2007-08-02 | Ace Biosciences A/S | Surface-located campylobacter jejuni polypeptides |
| EP1720905A2 (en) | 2003-12-11 | 2006-11-15 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
| US8828957B2 (en) | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
| WO2005103073A2 (en) | 2004-04-27 | 2005-11-03 | Intercell Ag | Td antigens |
| WO2005113598A2 (en) | 2004-05-21 | 2005-12-01 | Xencor, Inc. | Tnf super family members with altered immunogenicity |
| EP1768698A4 (en) | 2004-06-17 | 2009-01-28 | Medimmune Inc | IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES |
| WO2006012373A2 (en) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| KR101243577B1 (ko) | 2004-10-07 | 2013-03-20 | 아고스 쎄라퓨틱스, 인코포레이티드 | 성숙 수지상 세포 조성물 및 그의 배양 방법 |
| US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| GB0423681D0 (en) | 2004-10-26 | 2004-11-24 | Sec Dep For Environment Food & | Vaccine and nucleic acids |
| WO2006105972A1 (en) | 2005-04-07 | 2006-10-12 | Universite Libre De Bruxelles | Transgenic organism expressing cd40l and uses thereof |
| WO2006130525A2 (en) | 2005-05-31 | 2006-12-07 | Sidney Kimmel Cancer Center | Methods for immunotherapy of cancer |
| EP1909834A2 (en) | 2005-07-18 | 2008-04-16 | Critical Therapeutics, Inc. | Use of hmgb1 antagonists for the treatment of inflammatory skin conditions |
| SI1949913T1 (sl) | 2005-10-07 | 2011-02-28 | Proyecto Biomedicina Cima Sl | Imunsko stimulacijska kombinacija za zaĺ äśito in zdravljenje hepatitisa c |
| US9533036B2 (en) | 2005-11-07 | 2017-01-03 | Microvax, Llc | Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein |
| WO2007054658A1 (en) | 2005-11-14 | 2007-05-18 | King's College London | Control of immune responses |
| WO2007130725A2 (en) | 2006-02-06 | 2007-11-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of hmgb1 for protection against ischemia reperfusion injury |
| CU23576A1 (es) | 2006-02-28 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Antígenos vacunales quiméricos contra el virus de la influenza aviar |
| WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| US8802419B2 (en) | 2006-03-02 | 2014-08-12 | University Of Massachusetts | Modified pathogens for use as vaccines |
| CN101064542B (zh) | 2006-04-30 | 2010-12-08 | 中兴通讯股份有限公司 | Mimo ofdm系统中发射天线选择与自适应调制方法 |
| US9249202B2 (en) * | 2006-08-11 | 2016-02-02 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in immune disorders |
| US20100166788A1 (en) * | 2006-08-16 | 2010-07-01 | Novartis Vaccines And Diagnostics | Immunogens from uropathogenic escherichia coli |
| PT2066339E (pt) | 2006-09-18 | 2014-10-31 | Texas A & M Univ Sys | Composições e métodos de potenciar respostas imunes |
| WO2008109825A2 (en) | 2007-03-08 | 2008-09-12 | Mayo Foundation For Medical Education And Research | Inducing immune-mediated tumor cell death |
| WO2009059018A1 (en) | 2007-10-30 | 2009-05-07 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
| HUE047164T2 (hu) | 2007-11-01 | 2020-04-28 | Univ Arkansas | Kompozíciók és eljárások eimeria elleni immunválasz fokozására |
| JP2012530500A (ja) * | 2009-06-26 | 2012-12-06 | ヴェクトライト バイオメディカ インコーポレイテッド | サイトメガロウイルス由来のペプチドを含む免疫原組成物および使用方法 |
| GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
| NO2525817T3 (OSRAM) | 2010-01-21 | 2018-01-06 | ||
| WO2013071298A1 (en) | 2011-11-11 | 2013-05-16 | Nutrition Physiology Company, Llc | Lactic acid bacteria and their use as dietary supplementals for poultry |
| AU2011264772B2 (en) | 2010-06-09 | 2015-07-16 | The Board Of Trustees Of The University Of Arkansas | Vaccine and methods to reduce Campylobacter infection |
| EP2809347A1 (en) | 2012-02-01 | 2014-12-10 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Campylobacter immunogenic compositions and uses thereof |
| WO2014028776A1 (en) * | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| WO2014070709A1 (en) | 2012-10-29 | 2014-05-08 | The Board Of Trustees Of The University Of Arkansas | Novel mucosal adjuvants and delivery systems |
| EP2956165B1 (en) | 2013-02-14 | 2019-09-11 | The Board of Trustees of the University of Arkansas | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
| AR095313A1 (es) * | 2013-03-15 | 2015-10-07 | Univ Arkansas | Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos |
-
2014
- 2014-03-14 AR ARP140101015A patent/AR095313A1/es not_active Application Discontinuation
- 2014-03-14 EP EP14769698.3A patent/EP2968423A4/en not_active Ceased
- 2014-03-14 MX MX2015012855A patent/MX376350B/es active IP Right Grant
- 2014-03-14 BR BR112015023024-5A patent/BR112015023024B1/pt active IP Right Grant
- 2014-03-14 MY MYPI2015002375A patent/MY173901A/en unknown
- 2014-03-14 EP EP19173788.1A patent/EP3578190A1/en active Pending
- 2014-03-14 SG SG11201507421XA patent/SG11201507421XA/en unknown
- 2014-03-14 US US14/776,986 patent/US10376571B2/en active Active
- 2014-03-14 AU AU2014239557A patent/AU2014239557B2/en not_active Ceased
- 2014-03-14 WO PCT/US2014/027416 patent/WO2014152508A1/en not_active Ceased
- 2014-03-14 EA EA201591798A patent/EA033538B1/ru unknown
- 2014-03-14 HK HK16107045.2A patent/HK1219045A1/zh unknown
- 2014-03-14 CA CA2906079A patent/CA2906079C/en active Active
- 2014-03-14 JP JP2016502428A patent/JP6530742B2/ja active Active
- 2014-03-14 KR KR1020157028645A patent/KR102239207B1/ko active Active
- 2014-03-14 CN CN201480014526.3A patent/CN105142653B/zh active Active
-
2015
- 2015-09-03 ZA ZA2015/06466A patent/ZA201506466B/en unknown
- 2015-09-15 PH PH12015502135A patent/PH12015502135A1/en unknown
- 2015-09-15 CL CL2015002741A patent/CL2015002741A1/es unknown
-
2017
- 2017-11-22 CL CL2017002971A patent/CL2017002971A1/es unknown
-
2019
- 2019-08-05 US US16/531,893 patent/US10716840B2/en active Active
-
2020
- 2020-06-09 US US16/897,085 patent/US11013792B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6530742B2 (ja) | 腸内病原体の免疫応答を強化する組成物及び方法 | |
| JP6874031B2 (ja) | アイメリアに対する免疫応答を強化するか又はアイメリア感染症を制限する組成物及び方法 | |
| JP6687585B2 (ja) | 免疫応答を増強するワクチンベクターおよび方法 | |
| US11382962B2 (en) | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same | |
| MX2012014395A (es) | Vacuna y metodos para reducir una infeccion por campylobacter. | |
| NZ711761B2 (en) | Compositions and methods of enhancing immune responses to enteric pathogens | |
| HK1218880B (en) | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170307 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170307 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171218 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180903 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190131 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190418 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190517 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6530742 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |